Start › Niedrobnokomórkowy rak płuca › Floryda › St. Petersburg
Badania kliniczne dla Niedrobnokomórkowy rak płuca w mieście St. Petersburg, FL
21 badań dla Niedrobnokomórkowy rak płuca szuka uczestników w ośrodkach w mieście St. Petersburg i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
RekrutacjaFaza 2
- Comprehensive Hematology Oncology /ID# 270422, St. Petersburg
- Florida Cancer Specialists - North /ID# 271995, St. Petersburg
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekrutacjaFaza 3
- Moffitt Cancer Center at SouthShore, Ruskin · 15 mi dalej
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
RekrutacjaFaza 3
- Comprehensive Hematology Oncology, St. Petersburg
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekrutacjaFaza 3
- Saint Anthony's Hospital Cancer Care Center, St. Petersburg
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekrutacjaFaza 3
- Florida Cancer Specialists & Research Institute - North, St. Petersburg
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RekrutacjaFaza 3
- Research Site, St. Petersburg
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- Florida Cancer Specialists, St. Petersburg
- Florida Cancer Specialists, St. Petersburg
- Florida Cancer Specialists, Bradenton · 20 mi dalej
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekrutacjaFaza 2
- Florida Cancer Specialists & Research Institute 1, St. Petersburg
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- Florida Cancer Specialists North, St. Petersburg
- Comprehensive Hematology Oncology, St. Petersburg
Pan-tumor MRD Study
RekrutacjaBadanie obserwacyjne
- Comprehensive Hematology Oncology (CHO), St. Petersburg
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RekrutacjaFaza 3
- Florida Cancer Specialists - North, St. Petersburg
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RekrutacjaFaza 3
- Local Institution - 0695, St. Petersburg
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekrutacjaFaza 3
- Clinical Study Site, St. Petersburg
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekrutacjaFaza 2/3
- Local Institution - 007-922-D, Bradenton · 20 mi dalej
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekrutacjaFaza 1
- Comprehensive Hematology Oncology, St. Petersburg
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
RekrutacjaFaza 1/2
- Florida Cancer Specialists - NORTH - SCRI - PPDS, St. Petersburg
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekrutacjaFaza 3
- Comprehensive Hematology Oncology, St. Petersburg
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- Florida Cancer Specialists - NORTH - SCRI - PPDS, St. Petersburg
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RekrutacjaFaza 3
- Research Site, St. Petersburg
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekrutacjaFaza 1/2
- USOR Florida Cancer Specialists North, St. Petersburg
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekrutacjaBadanie obserwacyjne
- Saint Anthony's Hospital Cancer Care Center, St. Petersburg
Badania dla Niedrobnokomórkowy rak płuca w innych miastach
- Houston, TX145 badań
- New York City, NY121 badań
- Arlington, VA104 badań
- Nashville, TN97 badań
- Boston, MA90 badań
- Los Angeles, CA87 badań
- St. Louis, MO73 badań
- Chicago, IL61 badań
- Baltimore, MD60 badań
- San Antonio, TX59 badań
- Columbus, OH57 badań
- Washington, DC55 badań
Inne badania w mieście St. Petersburg
- Rak piersi11 badań
- Otyłość9 badań
- Nadwaga9 badań
- Rak jelita grubego i odbytnicy8 badań
- Niewydolność serca8 badań
- Rak płuc7 badań
- Rak endometrium6 badań
- Chłoniak Burkitta6 badań
- Rak jajnika6 badań
- Cukrzyca typu 25 badań
- POChP5 badań
- Ostra białaczka szpikowa5 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.